Japanese health supplement maker Kobayashi Pharmaceutical announced on Friday that it is investigating 76 additional deaths that may be linked to its cholesterol-lowering supplement containing red yeast rice, known as “Benikoji”.
“We have received 1,656 inquiries from individuals who have sought medical attention, and have 76 cases under investigation over a possible connection to the deaths,” the company stated.
Previously, five deaths had been officially reported to Japan’s health ministry in relation to the supplement. The supplement, marketed as a natural remedy to lower cholesterol levels, contains red yeast rice, a traditional ingredient in East Asian medicine.
The Osaka-based company has faced criticism for not disclosing the issue promptly, despite being aware of the problems internally since January. The first public announcement regarding the potential risks associated with the supplement was made on March 22.
The delays in alerting the public have raised concerns among consumers and health professionals. Kobayashi Pharmaceutical is now under scrutiny as it works with health authorities to determine the causal links between the supplement and the reported deaths.
Red yeast rice supplements have gained popularity for their purported benefits in managing cholesterol levels. However, they can contain monacolin K, a substance chemically identical to the active ingredient in certain prescription statins, which can have serious side effects.
The company has urged consumers who have used the supplement to seek medical advice if they experience any adverse symptoms. Investigations are ongoing to assess the safety of the product and to establish appropriate measures to protect public health.
Reference(s):
cgtn.com
